122 results about "Osteoporosis" patented technology

The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.

The invention belongs to the technical field of microbial function development, and particularly relates to lactobacillus plantarum YD666 and application of the lactobacillus plantarum YD666 in products for slowing down muscle atrophy and osteoporosis, the lactobacillus plantarum YD666 is preserved in the China Center for Type Culture Collection with the preservation number of CCTCC No: M 2025897, a preparation method of a lactobacillus plantarum YD666 bacterial suspension is provided, and the lactobacillus plantarum YD666 bacterial suspension can be used for preparing the lactobacillus plantarum YD666 bacterial suspension with the preservation number of CCTCC No: M 2025897. According to the lactobacillus plantarum YD666 and the application of the lactobacillus plantarum YD666 bacterial suspension in preparation of products for slowing down muscle atrophy and osteoporosis, the weight index of skeletal muscles of suspended tail rats can be increased by slowing down muscle weight loss caused by weightlessness; growth of muscle fibers is promoted, and the proportion of conversion from slow muscles to fast muscles is reduced, so that a weightlessness environment is resisted; the muscle movement contraction strength of the suspended tail rats is maintained, so that the application of relieving muscle atrophy under weightlessness is achieved, and the device is suitable for astronauts, crowds lack of movement and bedridden people who suffer from long-term illness and has wide market potential and application prospects.

A traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-13 parts of Acori Tatarinowii Rhizoma, 14-22 parts of Curcuma phaeocaulis, 14-22 parts of Cuscuta chinensis, 11-19 parts of oyster, 18-30 parts of Verbena officinalis, 12-19 parts of Schisandra chinensis, 14-22 parts of Poria cocos, 24-37 parts of Rhizoma Dioscoreae Hypoglaucae, 4-8 parts of licorice, and 4-9 parts of Indigo naturalis. The traditional Chinese medicine composition tonifies the kidney to consolidate the essence, and treats osteoporosis and prostatitis.

The invention relates to a beta-CTx binding antibody or an antigen binding fragment thereof, the beta-CTx binding antibody comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region contain HCDR and LCDR sequences; the invention also relates to corresponding isolated nucleic acid molecules, expression vectors and host cells. In addition, the invention also relates to a kit and a method for diagnosing osteoporosis in a subject.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention discloses an application of an AMPK (adenosine monophosphate kinase) activator or a PPAR (peroxisome proliferator activated receptor) gamma inhibitor in preparation of a medicine for preventing or treating diabetic osteoporosis. The invention discloses a key effect of a brand new signal channel, namely an AMPK-PPAR gamma-ERS axis, in osteogenic differentiation disorder of diabetes mellitus, and provides a method for preventing and treating diabetic osteoporosis by regulating and controlling the signal axis by taking metformin as a core. The invention provides new guidance for research and development of medicines for treating osteoporosis, and has potential clinical application and mechanism research values.

The invention relates to the technical field of gene therapy and drug development, and provides application of a UCH37 inhibitor in preparation of a drug for treating osteoporosis. The expression level of UCH37 in blood of osteoporosis patients is obviously higher than that of UCH37 in blood of healthy people, and the UCH37 is in positive correlation with osteoclast active markers such as NFATC1 and MMP9. The UCH37 inhibitor is applied to preparation of the medicine for treating osteoporosis and directly targets UCH37, the curative effect does not depend on the expression change of ADRM1, no matter the ADRM1 of osteoporosis patients is in a low or high expression state, an osteoclast activation pathway can be stably blocked, the consistency of treatment effects of different individuals is ensured, the range of applicable people of the medicine is expanded, and the application prospect is broad. The compound has the characteristics of clear action mechanism and wide application range, and provides important theoretical basis and conversion prospect for developing novel and efficient medicines for treating osteoporosis.

The present application relates to the technical field of multi-cause intelligent analysis in medical diagnosis, and particularly relates to an osteoporosis detection method and system based on data analysis and artificial intelligence. The method comprises the following steps: S1: obtaining primary osteoporosis data and secondary osteoporosis data and determining synergistic data, and determining antagonistic masking data according to the synergistic data; S2: obtaining a first layer dominant right conversion sequence according to the synergistic data and the antagonistic masking data; S3: obtaining a synergistic data internal dominant relationship sequence and an antagonistic masking data internal dominant relationship sequence respectively according to the synergistic data and the antagonistic masking data, and generating a complete dominant relationship graph in combination with the first layer dominant right conversion sequence. The present application separates and analyzes the synergistic and antagonistic modes of primary and secondary osteoporosis, constructs a dynamic dominant right sequence, quantifies the evolution of mixed cause weights, and provides data support for individualized precise diagnosis and treatment.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TREM2 in preparation of a diagnostic kit for chronic kidney disease osteoporosis. The invention finds that the TREM2 signal channel is closely related to the common pathological background of chronic kidney disease and osteoporosis. Therefore, the TREM2 can be used as an expression characteristic and a molecular diagnosis marker in the chronic kidney disease-related osteoporosis, so that the chronic kidney disease-related osteoporosis can be subjected to early diagnosis. On the basis, the invention provides application of the TREM2 detection reagent in preparation of the chronic kidney disease osteoporosis diagnosis kit, and the application prospect is good.

The application discloses an osteoporosis risk grading prediction method based on clinical prior logic gating, acquires multi-modal clinical data of a patient to obtain a standardized feature vector group, constructs and trains an osteoporosis risk grading prediction neural network model, including a double-flow feature coding module, a logic gating fusion module and a cascaded classification prediction module, inputs the standardized feature vector group after splicing processing to the trained neural network model, and outputs an osteoporosis risk grading prediction result. The application converts the diagnosis logic in the clinical guideline into an attention gating mechanism in the neural network by designing a double-flow architecture, and combines a screening-grading cascaded strategy, so that the existing structured data (demography, test single, medical history) in the hospital information system can be directly used to realize low-cost, high-precision and clinically interpretable osteoporosis risk grading without additional image examination.

The invention belongs to the field of medicaments, and discloses a nano-medicinal preparation capable of treating diabetes and a preparation method of the nano-medicinal preparation. The preparation method comprises the following steps: carrying out hydrothermal reaction on fructose-1, 6-strontium diphosphate, vanadium pentoxide and ergothioneine to prepare strontium-vanadate organic framework nanoparticles; the strontium-vanadate organic framework nano-particles, dopamine and polylysine are blended, embedding of polydopamine is achieved under the alkaline condition, polylysine-polydopamine co-embedded organic framework nano-particles are formed, and the nano-drug preparation for treating diabetes is obtained. The nano medicinal preparation can release the vanadyl complex and the ergothioneine and improve the blood strontium concentration and the half-life period thereof, so that the blood sugar is controlled, the symptoms of diabetes mellitus are improved, and the symptoms of osteoporosis, arteriosclerosis and the like complicated by diabetes mellitus are improved.

The invention relates to corn with the efficacy of preventing or improving osteoporosis symptoms. The mass ratio of campesterol to stigmasterol to beta-sitosterol in the corn is 1: (0.5-5): (1-5). The planted corn can significantly improve osteoporosis, and has the advantages of high yield of planted corn and corn straw, good taste, convenience in use, high bioavailability, safety, effectiveness, high comprehensive utilization rate of resources, greenness, environmental protection and the like.

The invention discloses a traditional Chinese medicine composition for treating spleen-kidney yang deficiency type osteoporosis, a preparation and application, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition is prepared from, by weight, 9-12 g of rhizoma curculiginis, 9-12 g of herba epimedii, 8-10 g of radix morindae officinalis, 8-10 g of radix angelicae sinensis, 3-6 g of cortex phellodendri, 3-6 g of rhizoma anemarrhenae, 9-12 g of radix rehmanniae praeparata, 10-15 g of rhizoma discoreae, 8-10 g of fructus psoraleae, 8-10 g of radix rehmanniae recen, 9-12 g of cortex eucommiae, 8-10 g of rhizoma chuanxiong, 12-15 g of poria cocos and 3-6 g of radix glycyrrhizae. The traditional Chinese medicine composition is suitable for spleen-kidney yang deficiency type osteoporosis. The traditional Chinese medicine composition can be used for treating deficiency-heat syndrome, deficiency-cold syndrome and phlegm-stasis collateral obstruction syndrome, so that the aim of treating according to symptoms is fulfilled. The prescription disclosed by the invention has the effects of strengthening the body resistance to eliminate pathogenic factors and treating both symptoms and root causes aiming at osteoporosis caused by spleen-kidney yang deficiency, bone withering and marrow reduction, blood stasis blockage and meridian obstruction. Clinical research shows that the medicine composition can effectively improve the symptoms such as intolerance of cold, lassitude and loose and firm muscles of osteoporosis patients after long illness, and is good in safety.

The invention discloses a preparation method of a nano copper selenide antibacterial peptide-loaded multistage microporous titanium alloy. The preparation method comprises the following steps: 1, preparing a substrate; 2, surface modification; and 3, carrying out functionalization treatment to obtain the multistage microporous titanium alloy loaded with the nano copper selenide antibacterial peptide. The invention further provides the multistage microporous titanium alloy loaded with the nano copper selenide antibacterial peptide. The load design and photo-thermal synergistic mechanism of the nano copper selenide antibacterial peptide-loaded multistage microporous titanium alloy can effectively inhibit bacterial breeding and greatly reduce the infection risk of implantation operations, and on the aspect of promoting osseointegration, the multi-scale structure and ion slow release design can accelerate bone tissue growth and material fusion and reduce long-term complications, so that the titanium alloy can be used as a medical material for treating osteoporosis. The bone repair microenvironment is optimized, a new thought, good stability and safety are developed for complex disease treatment, long-term stable effect in vivo is guaranteed, strict standards are met, a solid foundation is laid for large-scale clinical application, and the bone implantation medical field is expected to be innovated.

The invention discloses a imperatorin and icariin composition and application thereof in preparation of medicines for treating osteoporosis, and belongs to the field of biological medicines. According to the invention, imperatorin and icariin in a mass ratio of 1: (1-5) are prepared into the pharmaceutical composition, and the pharmaceutical composition is applied to treatment of osteoporosis. Cell experiment and in-vivo experiment results show that the pharmaceutical composition provided by the invention has various pharmacological activities of regulating hormone and cell factor levels, resisting osteoclast absorption, promoting osteoblast generation and the like, and can also effectively increase the bone mineralization density of osteoporosis model mice. Based on natural traditional Chinese medicine active ingredients, the medicine which is efficient, low in toxicity and rich in pharmacological activity is provided for treatment of osteoporosis, and the medicine has outstanding clinical application value and wide application prospects.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The invention discloses a three-channel bionic bone organ chip and a method thereof.The three-channel bionic bone organ chip comprises a three-channel model and a carrier, the three-channel model comprises a blood vessel channel in the middle and bone channels located on the two sides of the blood vessel channel, the width of the blood vessel channel is 500 micrometers, the width of the bone channels is 1000 micrometers, and the width of the carrier is 100 micrometers. The two sides of the blood vessel channel are separated from the bone channels on the two sides through long barriers respectively. The carrier is used for bearing the three-channel model. According to the invention, a novel bone organ chip (Bone Orga-on-a-Chip, BOC) is constructed, which is convenient for simulating an OP microenvironment induced by glucocorticoid and the influence of mechanical mechanics on treatment of OP by MSCs. On the basis, a candidate gene TPD52L1 is further analyzed and screened through bioinformatics, the candidate gene TPD52L1 is remarkably up-regulated in MSCs induced osteogenic differentiation, and the effect of the gene in MSCs osteogenic adipogenic fate choice is discussed.

The invention relates to application of ITGBL1 as a medicine for treating obesity and osteoporosis. The invention provides a treatment strategy based on a key molecular mechanism of obesity and osteoporosis associated pathogenesis. The invention discloses ITGBL1 treatment which can inhibit obesity and osteoporosis.

The invention provides an application of miR-337 in preparation of a medicine for treating osteoporosis, which is used for the medicine for treating osteoporosis, and relates to the technical field of biomedicine. The research of the inventor finds that miR-337 can activate p53 to promote apoptosis of osteoclasts, has a certain treatment effect on osteoporosis, and can be used for preparing the medicine for treating osteoporosis; the nano vesicles derived from human umbilical cord mesenchymal stem cells have certain anti-inflammatory activity and have a positive effect on treatment of osteoporosis. According to the application disclosed by the invention, miR-337 is further loaded on nano vesicles derived from human umbilical cord mesenchymal stem cells, and the research of the inventor finds that the medicine has a good treatment effect on osteoporosis, provides a new strategy for preventing postmenopausal osteoporosis, and has remarkable clinical transformation potential.

The invention discloses a bionic bimetallic polyphenol network nano-drug loaded with small non-coding RNA and a preparation method and application thereof, and belongs to the technical field of nano biomedicine.The nano-drug is loaded with small interference through a bimetallic polyphenol network, the surface of the nano-drug is coated with an M1 type macrophage membrane, and the safe and effective nano-drug is formed; the nano-drug acts on macrophages of an inflammation joint part, ROS is synergistically cleared by releasing tannic acid, Cu < 2 + > and small interfering RNA, TNF-alpha expression is inhibited, macrophage polarization is induced, meanwhile, Sr < 2 + > further plays a role in cartilage protection, and the purpose of treating osteoporosis and rheumatoid arthritis is achieved.

Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a —COOH group or a —OH group; R3′ and R3″ represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; R4 and R5 represent a hydrogen atom, a halogen atom, a —IMH2 group, a (C1-C3)alkyl group, a (C1-C3)alkoxy group, or a —OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a ═NOCH3 group or a (C3-C5)cycloalkyl group; R7 represents a hydrogen atom, a methyl group, a —OH group or a fluorine atom; R6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 3 to 8 membered-heterocycloalkyl group, a (C1-C6)alkyl group or a phenyl (C1-C2) alkyl group; X represents —CH2—, —O— or —S—; Y represents —CH═, —N═ or —CR″═; R8 represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; R9 represents a hydrogen atom or a fluorine atom; RIO and RIO′ represent a hydrogen atom or a fluorine atom; R11 represents a hydrogen atom a (C1-C3)alkyl group or a cyclopropyl group; n is 0, 1 or 2, and m is 0 or 1. Further disclosed are process for preparing the same, pharmaceutical compositions comprising them as well as said compounds of formula (I) for use as an inhibitor and degrader of estrogen receptors, in particular in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

The application belongs to the technical field of medical products and health products, and particularly relates to a compound targeting sclerostin and application thereof. A novel small-molecule compound is found and prepared, the small-molecule compound has good sclerostin binding capacity, sclerostin inhibition and the like, and can be used as a candidate drug for preventing or treating osteoporosis and bone fracture.

The invention discloses application of oxidized berberine and berberrubine in treatment of diabetic osteoporosis, and belongs to the technical field of biological medicine. Researches find that both oxidized berberine and berberrubine have the effect of treating diabetic osteoporosis, and can significantly improve the femur microstructure of a diabetic osteoporosis model animal, so that the femur microstructure recovers to a normal level; the blood glucose clearing capacity can be improved, the insulin resistance index is reduced, and the insulin signal channel function is recovered; the oxidative stress state of diabetic osteoporosis model animals can be relieved, the proinflammatory factor level is reduced, and the anti-inflammatory and anti-oxidation effects are achieved. The invention provides a new scheme and data support for the treatment of diabetic osteoporosis, has better curative effect, safety and economy than the prior art, and has important clinical transformation value.

SOLUTION: To provide a method for extracting DNA from fish and a method for using a DNA extract.EFFECT: The DNA extract has an effect of improving or treating osteoarthritis or osteoporosis. In addition, the DNA extract exhibits free radical scavenging activity, antioxidant activity, antidepressant activity, and black hair promoting activity.SELECTED DRAWING: None

The invention discloses an acacetin and isonicotinamide eutectic, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and isonicotinamide, and the molecular formula of the eutectic substance is (C16H12O5). (C6H6N2O), the invention relates to a preparation method of a cocrystal of acacetin and isonicotinamide. The acacetin and isonicotinamide eutectic is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.

The application discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in the postmenopausal intestinal tract and relieving postmenopausal intestinal inflammation, and belongs to the medical field. The pinoresinol diglucoside can regulate the abundance of Akkermansia, another branch bacteria, parabacteroides, rumenococcus and other genera in the intestinal tract, promote the expression of short-chain fatty acids in the postmenopausal intestinal tract, and then relieve postmenopausal intestinal inflammation and osteoporosis. The application opens up a new clinical approach for the treatment of postmenopausal women and diseases related to intestinal flora disorder.

The present application relates to a kind of gRNA targeted to non-human animal OPG gene, preparation method of OPG gene knockout non-human animal model.The preparation method of OPG gene knockout non-human animal model includes the following steps: using gene editing technology, destroy non-human animal OPG gene, for the gRNA targeted to non-human animal OPG gene includes one or two shown in SEQ ID NO:1 And / or SEQ ID NO:2.The present application designs the gRNA specifically targeted to non-human animal OPG gene, using Cas9 protein, OPG gene is knocked out, causes frame shift mutation, to reach the purpose of gene knockout to non-human animal.The method of the present application to non-human animal OPG gene modification is simple and easy to operate, short cycle, using the method of OPG model for research OPG gene physiological mechanism and molecular mechanism provides foundation, while providing important tool for research osteoporosis pathogenesis and drug development.